Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bifeprunox Open-Label Extension in Schizophrenia
NCT00366171Phase 3Completed
- Sponsor
- Pfizer
- Start
- Nov 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of bifeprunox in schizophrenia, sponsored by Pfizer. Started Nov 2006; status: completed.
02
Drugs
bifeprunox
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00366171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00366171.